Park Medi World and Nephrocare Health Services IPOs close today. Here’s the latest on subscription status, grey market premium (GMP), price band, key dates, and what analysts are saying.
Dec 12, 2025 (Friday) is crunch day for India’s primary market watchers: two healthcare mainboard IPOs—Park Medi World and Nephrocare Health Services—are in their final session of bidding, with investors tracking subscription momentum, grey market cues, and broker views right up to the close.
Both issues are positioned as plays on India’s expanding healthcare demand, but they sit in very different corners of the sector:
- Park Medi World: a multi-speciality hospital chain (healthcare delivery, asset-heavy expansion).
- Nephrocare Health Services: a large dialysis network (chronic care services, more “asset-light” in its operating model). Business Standard+1
Below is what’s new and most relevant as of Dec 12, 2025, based on publicly reported subscription data up to Day 2 (Dec 11) and the latest published market coverage.
What’s happening today: final day pressure on subscriptions
As of end of Day 2 (Dec 11, 5:00 pm IST):
- Park Medi World IPO was about fully subscribed (~0.98x overall), with stronger traction in retail and non-institutional segments, while QIB participation remained comparatively lower.
- Nephrocare Health Services IPO was still under-subscribed (~0.36x overall), reflecting a more cautious response so far.
That said, IPO demand can shift sharply on the last day—especially if institutional (QIB) bids come in late, which is common in book-built issues.
Quick facts: Park Medi World IPO
Issue size: ₹920 crore (Fresh issue ₹770 crore + OFS ₹150 crore)
Price band: ₹154–₹162 per share
Lot size: 92 shares
IPO dates: Dec 10–Dec 12, 2025
Tentative listing: Dec 17, 2025 (BSE, NSE)
Allotment (expected): Dec 15, 2025
Park Medi World IPO subscription: what Day 2 told investors
Coverage through Day 2 captured a clear story: interest improved through the day, but it wasn’t a runaway oversubscription early on.
- Mid-day Day 2 updates showed Park Medi World hovering below full subscription (e.g., around 0.77x by early afternoon in one tracker update).
- Exchange-based reporting by end of Day 2 put overall demand near 0.98x.
Category mix matters. Day 2 snapshots showed retail and NII demand doing more of the early lifting, while QIB demand lagged. For example, Moneycontrol’s Day 2 snapshot showed Retail ~1.19x and NII ~1.38x, versus QIB ~0.32x.
GMP check: what the grey market is hinting (and what it isn’t)
Grey market premium (GMP) chatter around Park Medi World has been modest and volatile—and different trackers reported different numbers at different times.
- Business Standard reported Park Medi World’s GMP around ₹10.5 (about 6.5%) at one point on Day 2.
- Groww’s Day 2 coverage cited GMP around ₹14.
- Financial Express cited GMP around ₹12 in its Day 2 coverage.
Important: GMP is unofficial and can change quickly with broader market sentiment and last-day bidding.
Business model and why analysts are watching it
Park Medi World is being pitched as a scale-up story in hospital delivery, with an acquisition-led “buy and fix” approach in North India, and a revenue mix heavily driven by in-patient services. INDmoney+1
Some of the key talking points highlighted in research-style coverage:
- High dependence on IPD revenue (admitted patients rather than walk-ins), and a significant share linked to government schemes/PSU business, which can support volumes but also exposes cashflows to policy and payment-cycle risks.
- Use of IPO proceeds: a major chunk earmarked for debt reduction (₹380 crore), plus capex like a new hospital project and medical equipment purchases, with remaining proceeds for corporate purposes and future acquisitions.
- Valuation framing: some brokerage commentary cited the issue being valued around 25x on annualised earnings at the upper band, and positioned it as a longer-term healthcare delivery play.
The risks being discussed (and why they matter on Day 3)
The most pointed investor questions aren’t about demand today—they’re about execution after listing:
- Occupancy and utilisation: some analysis notes occupancy declining toward the ~60–62% range in recent periods (versus higher levels earlier), raising the challenge of filling beds while carrying fixed operating costs.
- Concentration risk: revenue concentration by geography and payer type (state + government/PSU exposure) can cut both ways.
- Expansion execution: planned bed additions and acquisitions can lift scale, but also increase the complexity of staffing, ramp-up, and cash conversion—especially if working capital cycles remain long.
Quick facts: Nephrocare Health Services IPO
Issue size: ₹871.05 crore (Fresh issue ₹353.4 crore + OFS ~₹517.64 crore)
Price band: ₹438–₹460 per share
Lot size: 32 shares
IPO dates: Dec 10–Dec 12, 2025
Tentative listing: Dec 17, 2025 (BSE, NSE)
Anchor investment: company reported raising about ₹260 crore from anchor investors ahead of the issue.
Nephrocare IPO subscription: muted so far, with the “late QIB bid” question looming
On Day 2, the headline was simple: demand improved but stayed subdued overall.
- PTI-style coverage carried by ETHealthworld reported the issue at ~36% subscribed on Day 2.
- Moneycontrol’s Day 2 snapshot similarly reflected ~0.36x overall, with category demand still under 1x across the board at that stage.
As with Park Medi World, many investors watch whether QIB participation arrives late on the final day—often a swing factor for book-built deals.
GMP check: improving sentiment, but not “hot”
Nephrocare’s GMP signals have generally been moderate:
- Business Standard cited a GMP around ₹20 (about 4.35% over the upper issue price) in its day-two comparison coverage.
- Economic Times’ market coverage similarly described the grey market moving up to roughly 4.35% premium, after being near zero earlier.
Again, GMP is not a guarantee—just a temperature check in an unofficial market.
The big story: dialysis as “recurring demand” healthcare
Unlike hospital operators, dialysis networks are often pitched on:
- recurring patient demand,
- protocol-driven standardised services,
- and expansion via partnerships (including within hospitals).
Nephrocare is positioned as a scale platform: ETMarkets described it as India’s largest dialysis care provider, with a reported 519 clinics across India and international markets and a large tier-II/tier-III footprint.
The company’s recent financial trajectory has also featured in coverage:
- ETMarkets reported revenue expansion and a return to profitability, including FY25 net profit around ₹67 crore and improved margins in recent years.
Where the fresh money is expected to go
Multiple reports converged on a similar use-of-proceeds plan for the fresh issue:
- fund new dialysis clinics (capex and setup),
- repay/prepay part of debt,
- and support general corporate purposes.
Risks investors are weighing
Nephrocare’s risks are different from hospital-chain risks—and much more about contracts, receivables, and partnerships:
- ETMarkets highlighted reliance on PPP contracts and captive clinics inside hospitals, and noted receivable-day concerns for PPP clinics.
Park Medi World vs Nephrocare: how investors are comparing the two on Dec 12
With both IPOs closing today, the real question is less “which is better?” and more which business model aligns with what an investor is actually buying.
1) Asset-heavy hospital chain vs “asset-light” chronic-care network
- Park Medi World: hospitals typically mean higher fixed costs, higher capex per location, and bigger dependence on occupancy and case mix.
- Nephrocare: dialysis networks lean toward repeat utilisation, standardisation, and clinic rollouts, but can be more sensitive to partner/hospital relationships and PPP payment cycles.
2) Subscription patterns: what the bidding data suggested
As of Day 2, the market’s revealed preference looked like this:
- Park Medi World was near full subscription, supported more by retail/NII segments early on.
- Nephrocare was still well below full subscription, with softer traction across categories.
3) What brokerages have been saying publicly
Business Standard’s roundup reflected a broadly constructive tone on both, but with different “why”:
- Park Medi World: some broker notes pointed to sector growth tailwinds, network strategy, profitability metrics, and debt paydown as a positive lever.
- Nephrocare: commentary leaned on its scale, recurring demand characteristics, and expansion roadmap—often framed as a “long-term” subscription call. Business Standard+2Business Standard+2
What to watch before the window closes today
If you’re following these IPOs on Dec 12, the late-day checklist is straightforward:
- Final-day QIB participation
A late surge (or lack of it) can meaningfully change the subscription headline at close. - Latest subscription cut-off time
Different media updates can reflect different snapshots during the day; always note whether a figure is mid-session or end-of-day. - GMP trend, not GMP point
Across both IPOs, GMP has been positive but not euphoric—and has moved around by tracker and time. - Post-IPO calendar
Both IPOs have a similar near-term timeline: expected allotment around Dec 15 and tentative listing around Dec 17 (subject to final schedules).
Bottom line
Park Medi World IPO entered the final day with near-full subscription after Day 2, supported mainly by retail/NII interest, while Nephrocare Health Services IPO remained under-subscribed through Day 2 and is more dependent on whether late institutional bids change the picture.
From an investor-story perspective, the decision comes down to what you want exposure to:
- hospital delivery + expansion execution (Park Medi World), or
- chronic-care dialysis + network scale and partnerships (Nephrocare).
